ClinicalTrials.gg
CompletedNCT05876949Updated May 15, 2025Results posted

AVT03 With Xgeva in Healthy Male Subjects

A Phase 1 interventional study of AVT03 and Denosumab in This is a Phase I Study Conducted in Healthy Volunteers, sponsored by Alvotech Swiss AG. Completed at 3 sites in 3 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
28 Years to 55 Years
Sex
Male
01

Study summary

This study has been designed as a randomized, double-blind, parallel-group study and in healthy adult male subjects of age 28 years to 55 years old. The study will assess the PK, safety and tolerability of AVT03 compared to US-Xgeva when administered as a single 120 mg SC dose

Read the detailed description

The study will consist of screening period, a 196 day (28 weeks) treatment and assessment period, and an End of Study (EOS) visit on week 32 on Day 196. Subjects will undertake a screening visit between Day -28 and Day -1 to determine their eligibility for the study. Subjects who meet the eligibility criteria will be admitted to the study site on the day prior to dosing (Day -1), during which their continued eligibility will be assessed up to Day 1 prior to dosing. On Day 1, eligible subjects will be randomized and will receive a single dose of 120mg AVT03 or 120mg Xgeva as subcutaneous injection.

02

Conditions studied

  • This is a Phase I Study Conducted in Healthy Volunteers

Keywords

  • Denosumab
  • Healthy Volunteers
03

In context

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  2. Male subjects who are 28 to 55 years old, inclusive, at the time of signing the ICF.
  3. Have a body weight of 50.0 to 90.0 kg (inclusive) and of 17.0 to 32 kg/m2 at Screening and Day -1.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of pathology, especially prior diagnosis of bone disease, or any uncontrolled condition that will affect bone metabolism such as, but not limited to: osteoporosis, osteogenesis imperfecta, hyperparathyroidism,, non-controlled hyperthyroidism osteomalacia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, current flare-up of osteoarthritis and/or gout, active , renal disease, Paget's disease of the bone, malabsorption syndrome.
  2. Have osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (e.g., tooth extraction, dental implants, oral surgery) or intend to undergo such procedures during the study period, poor oral hygiene, periodontal, and/or pre-existing dental disease.
  3. Have bone fractures, presence of active healing fractures, or recent bone fracture
  4. Abnormal serum calcium.
  5. Known vitamin D deficiency.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Experimental Arm AVT03 120mg

    AVT03 is the proposed biosimilar for Xgeva (denosumab). Subjects in this arm will receive a single 120mg dose of AVT03 as a subcutaneous injection

    Biological: AVT03

  • Active comparator
    Active Comparator Xgeva 120mg

    Xgeva (denosumab) is the proposed active comparator for AVT03. Subjects in this arm will receive a single 120mg dose of Xgeva (denosumab) as a subcutaneous injection

    Biological: Denosumab

Interventions

  • BiologicalAVT03

    AVT03 will be given as 1 time subcutaneous injection

    Also known as: AVT03 proposed Biosimilar to Denosumab

  • BiologicalDenosumab

    Xgeva (denosumab) will be given as 1 time subcutaneous injection

    Also known as: Xgeva

06

What researchers measure

Primary outcomes

  1. Co-primary PK Endpoint Cmax: Maximum Serum Concentration

    Samples will be collected for measurement

    Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study

  2. Co-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation

    Samples will be collected for measurement

    Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study

Secondary outcomes

  1. PK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity.

    Samples will be collected for measurement

    Time frame: Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study

  2. Safety Incidence, Nature and Severity of Adverse Events.

    Time frame: Day 1(week 1) to Day 196 (week 28)]

  3. Immunogenicity Presence of ADAs and Presence of nAbs Against AVT03 and Xgeva

    Samples will be collected for measurement

    Time frame: Day 1, Day 8, Day 15, Day 29, Day 57, Day 71, Day 112, Day 141, Day 196/EoS

07

Results

Posted May 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
Started104104
Completed10398
Not completed16
Withdrew: Withdrawal by subject13
Withdrew: Physician decision02
Withdrew: Death01

Outcome measures

PrimaryCo-primary PK Endpoint Cmax: Maximum Serum Concentration

Samples will be collected for measurement

Time frame:
Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
Reported as:
Geometric mean · ng/mL
Co-primary PK Endpoint Cmax: Maximum Serum Concentration
ng/mLExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
Co-primary PK Endpoint Cmax: Maximum Serum Concentration12761.4 ± 3412259.8 ± 32
PrimaryCo-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation

Samples will be collected for measurement

Time frame:
Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
Reported as:
Geometric least squares mean · ng·h/mL
Co-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation
ng·h/mLExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
Co-primary PK endpoint_AUC0-t: Area Under the Serum Concentration-time Curve up to Time t, Where t is the Last Time Point With a Concentration Above the Lower Limit of Quantitation15501387.9 ± 2714366056.2 ± 29
SecondaryPK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity.

Samples will be collected for measurement

Time frame:
Day 1 (pre-dose, 8h and 12h post-dose), Day 2 to Day 13 (daily), Day 15, Day 18, Day 22, Day 25, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 112, Day 126, Day 141, Day 162 and Day 196 (week 28) / End of study
Reported as:
Geometric mean · ng·h/mL
PK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity.
ng·h/mLExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
PK_ AUC0-inf: Comprised of AUC0-t and AUC Extrapolated From Time t to Time Infinity.15559245.8 ± 2814555779.3 ± 29
SecondarySafety Incidence, Nature and Severity of Adverse Events.
Time frame:
Day 1(week 1) to Day 196 (week 28)]
Reported as:
Number · participants
Safety Incidence, Nature and Severity of Adverse Events.
participantsExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
Any TEAE6667
TESAEs13
SecondaryImmunogenicity Presence of ADAs and Presence of nAbs Against AVT03 and Xgeva

Samples will be collected for measurement

Time frame:
Day 1, Day 8, Day 15, Day 29, Day 57, Day 71, Day 112, Day 141, Day 196/EoS
Reported as:
Count of participants · Participants
Immunogenicity Presence of ADAs and Presence of nAbs Against AVT03 and Xgeva
ParticipantsExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
Binding (ADA)104102
Neutralizing Antibodies4143

Adverse events

Collected over All AEs/SAEs were recorded from the time of signing the ICF until the end of the subject's participation in the study, up to 32 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Arm AVT03 120mg0/104 (0%)1/104 (1%)66/104 (63.5%)
Active Comparator Xgeva 120mg1/104 (1%)3/104 (2.9%)67/104 (64.4%)
Most frequent serious events
Most frequent serious events
EventExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
PneumoniaInfections and infestations0/1041/104
Small bowel obstructionGastrointestinal disorders1/1040/104
HepatitisHepatobiliary disorders0/1041/104
Alcohol use disorderGeneral disorders0/1041/104
Most frequent other events
Showing 10 of 106
Most frequent other events
EventExperimental Arm AVT03 120mgActive Comparator Xgeva 120mg
NasopharyngitisInfections and infestations11/10411/104
Upper respiratory tract infectionInfections and infestations11/10410/104
HeadacheNervous system disorders10/1047/104
Blood creatine phosphokinase increasedInvestigations8/1045/104
InfluenzaInfections and infestations5/1046/104
NeutropeniaBlood and lymphatic system disorders5/1041/104
Blood pressure increasedInvestigations5/1042/104
DiarrhoeaGastrointestinal disorders3/1044/104
Injection site reactionGeneral disorders3/1044/104
COVID-19Infections and infestations1/1044/104

Baseline characteristics

Participants were healthy males aged 28 to 55 years.

Age, Continuous
Age, Continuous(years)Experimental Arm AVT03 120mgActive Comparator Xgeva 120mgTotal
Mean36.5 ± 6.7238.1 ± 7.0837.3 ± 6.94
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm AVT03 120mgActive Comparator Xgeva 120mgTotal
Female000
Male104104208
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental Arm AVT03 120mgActive Comparator Xgeva 120mgTotal
Asian (Japanese)121224
Black or African American282452
Caucasian/White6468132
08

Study locations

3 sites
  • Biokinetica
    Józefów, Poland
  • Farmovs
    Bloemfontein, South Africa
  • Richmond Pharmacology
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Apr 2024, 8 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 26, 2023
StartActual
Jul 21, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Results first posted
May 15, 2025
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05876949
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jul 21, 2023
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Results posted
May 15, 2025
Last update
May 15, 2025

Study contacts

Felicitas Bullo
study director · Alvotech Swiss AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVT03

Start the discussion